Effect of Extended Cannabis Abstinence on PTSD Symptoms
Key facts
- Who runs it
- Centre for Addiction and Mental Health
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 24 people enrolled
- Started
- 2 Feb 2022
- Ended
- 1 Sept 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Contingency-management
- Enhanced usual care
- Record updated
- 23 October 2026
Who can take part
- Age
- 18 years to 55 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Subjects aged between 18 and 55 years (from both sexes [or genders])
- Diagnosed with CUD (moderate or severe) according to the Structured Clinical Interview for DSM-IV (SCID) (mode of cannabis consumption can be inhalation or ingestion)
- Diagnosis of current (past 30 days) PTSD, using the CAPS-5 on screening
- On antidepressant medication(s) for at least 1 month (to ensure safety and homogeneity as PTSD treatment of our population)
- Be able to provide written informed consent; and
- Be able to communicate in English
Who cannot take part
- diagnosed with a severe or unstable medical illness that precludes safe participation in the study as per the study physician
- diagnosed with schizophrenia, schizoaffective disorder, or bipolar disorder or current acute psychosis or mania based on DSM-5 criteria
- current suicidality risk as indicated by the Columbia Suicide Severity Rating Scale (C-SSRS) with concurrence after the study physician's evaluation if the response to C-SSRS questions 1 or 2 is "yes" 34; and
- have pain interfering with normal function as reported by the 12-Item Short Form Survey (SF-12) (moderate or higher interference)
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This will be a 12-week randomized trial. Outpatients and patients from the Mood and Anxiety program at the Centre for Addiction and Mental Health (CAMH) with a current diagnosis of post-traumatic stressed disorder (PTSD) and cannabis-use disorder (CUD) will be randomized to receive individual motivational interviewing therapy and contingency management (n = 12) or individual motivational interviewing therapy alone (control group, n = 12) after enrolment.
The 2 groups in the trial
- Contingency management groupExisting treatment, for comparison
Randomized to receive individual motivational interviewing therapy and contingency management
Treatment: Contingency-management and Enhanced usual care
- Control groupOther group
Randomized to receive individual motivational interviewing therapy alone
Treatment: Enhanced usual care
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Publications
- The Effects of Extended Cannabis Abstinence in Comorbid Posttraumatic Stress Disorder and Cannabis Use Disorder.The Journal of clinical psychiatry, 2026
- Record updated
- 23 October 2026